LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates – News-Medical.net

Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore…

Click here to view the original article.